Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-06T10:14:27.159Z Has data issue: false hasContentIssue false
  • English
  • Français

Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm

Published online by Cambridge University Press:  19 February 2018

Marie-Paule Guillaume ,
Héloïse Reumaux  and
François Dubos
Marie-Paule Guillaume*
Affiliation:
Pediatric Cardiology, CHU Lille and University of Lille, Lille, France
Héloïse Reumaux
Affiliation:
Pediatric Rheumatology Unit, CHU Lille and University of Lille, Lille, France Pediatric Emergency unit and Infectious Diseases, CHU Lille and University of Lille, Lille, France
François Dubos
Affiliation:
Pediatric Emergency unit and Infectious Diseases, CHU Lille and University of Lille, Lille, France
*
Author for correspondence: M.-P. Guillaume, Pediatric Cardiology, Institut Coeur-Poumon, University Hospital of Lille, France. Boulevard Prof J Leclercq, 59000 Lille, France. Tel: +33 3 20 44 69 49; Fax: + 33 3 20 44 54 56; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Kawasaki disease is an acute self-limited vasculitis of unknown aetiology. The prognosis depends mainly on coronary damage. There is no consensus regarding optimal adjunctive therapeutics for refractory forms to treatment by intravenous immunoglobulins and corticosteroids. We report the case of an 18-month-old infant with refractory Kawasaki disease complicated by diffuse aneurysms of coronary arteries and successfully treated by anakinra with partial regression of coronary aneurysms

Keywords

Refractory Kawasaki diseasecoronary aneurysmanakinrachildren
Type
Brief Report
Information
Cardiology in the Young , Volume 28 , Issue 5 , May 2018 , pp. 739 - 742
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Burns, JC, Kushner, HI, Bastian, JF, et al. Kawasaki disease: a brief history. Pediatrics 2000; 106: E27.Google Scholar
2. McCrindle, B, Rowley, A, Newburger, J, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. A scientific statement for health professionals from the American Heart Association. Circulation 2017; 135: e927–e999.Google Scholar
3. Kobayashi, T, Kobayashi, T, Morikawa, A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr 2013; 163: 521–526.Google Scholar
4. Brogan, P, Levin, M. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease. Evid Based Med 2013; 18: 217–218.CrossRefGoogle ScholarPubMed
5. Orenstein, JM, Shulman, ST, Fox, LM, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One 2012; 7: e38998.Google Scholar
6. Hoang, LT, Shimizu, C, Ling, L, et al. Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. Genome Med 2014; 6: 541.Google Scholar
7. Lee, Y, Schulte, DJ, Shimada, K, et al. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation 2012; 125: 1542–1550.Google Scholar
8. Cohen, S, Tacke, CE, Straver, B, et al. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann Rheum Dis 2012; 71: 2059–2061.Google Scholar
9. Shafferman, A, Birmingham, JD, Cron, RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J 2014; 12: 26.CrossRefGoogle ScholarPubMed
10. Sánchez-Manubens, J, Gelman, A, Franch, N, et al. A child with resistant Kawasaki disease successfully treated with anakinra: a case report. BMC Pediatr 2017; 17: 102.Google Scholar
11. Dusser, P, Koné-Paut, I. IL-1 inhibition may have an important role in treating refractory Kawasaki disease. Front Pharmacol 2017; 8: 163.CrossRefGoogle ScholarPubMed

Guillaume et al. supplementary material

Supplementary Material 1

Download Guillaume et al. supplementary material(Video)
Video 2 MB
Supplementary material: Image

Guillaume et al. supplementary material

Supplementary Material 2

Download Guillaume et al. supplementary material(Image)
Image 369.1 KB